Grown Rogue International (GRUSF) Non Operating Income (2011 - 2026)
Grown Rogue International's (GRUSF) quarterly Non Operating Income came in at -$1.8 million in Q1 2026, down 186.21% year-on-year from $2.1 million in Q1 2025, and up 100.0% quarter-over-quarter from -$7349.3 billion in Q4 2025.
Grown Rogue International (GRUSF) Non Operating Income (2011 - 2026) Analysis & Trends
Grown Rogue International's Non Operating Income history runs 5 years deep, the most recent figure standing at -$1.8 million for Q1 2026.
- On a quarterly basis, Non Operating Income fell 186.21% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was -$4803.7 billion, a 140.47% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, up 144.57% from the prior year.
- Non Operating Income rose to -$1.8 million in Q1 2026 per GRUSF's latest filing, from -$7349.3 billion in the prior quarter.
- Across five years, Non Operating Income topped out at $13256.2 billion in Q4 2024 and bottomed at -$7349.3 billion in Q4 2025.
- The 4-year median for Non Operating Income is -$194852.0 (2023), against an average of $642.5 billion.
- Across the five-year window, Non Operating Income jumped 2104792095.96% in 2024 and tumbled 186.21% in 2026, its largest moves.
- Year by year, Non Operating Income stood at $629812.0 in 2023, then soared by 2104792095.96% to $13256.2 billion in 2024, then slumped by 155.44% to -$7349.3 billion in 2025, then soared by 100.0% to -$1.8 million in 2026.
- Per Business Quant, the three latest GRUSF Non Operating Income figures stand at -$1.8 million (Q1 2026), -$7349.3 billion (Q4 2025), and $2545.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | -1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.80 Mn |
| Dec 31, 2025 | -7,349.32 Bn |
| Sep 30, 2025 | 2,545.62 Bn |
| Jun 30, 2025 | 2.54 Mn |
| Mar 31, 2025 | 2.08 Mn |
| Dec 31, 2024 | 13,256.23 Bn |
| Sep 30, 2024 | -1,385.07 Bn |
| Jun 30, 2024 | -7.15 Mn |
| Mar 31, 2024 | -4.72 Mn |
| Dec 31, 2023 | 629,812.00 |
| Apr 30, 2023 | -194,852.00 |
| Nov 30, 2011 | 246,214.36 |
| Feb 28, 2011 | -84,234.48 |